(120) found that about 70% of TNBC L1 + breast cancer cells also expressed IDO, suggesting that IDO-related T cell damage may be the mechanism of anti-PD-1/PD-L1 immunotherapy drug resistance. The gene discussed is IDO1; the disease is breast cancer.